This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

XARELTO - Video: effects of PCC on XARELTO

Last updated : 08/25/2025

Specific response

Menu

• Specific response
• Related information
  • Executive summary
  • Video: effects of PCC on XARELTO
  • Reversal agents in human studies
    • PCC
      • Levi et al (2014)
      • Eerenberg et al (2011)
      • Schulman et al (2018)
    • aPCC
      • Sheikh-Taha et al (2023)
      • Perzborn et al (2014)
    • aPCC and PCC
      • Escolar et al (2015)
    • Andexanet alfa (PRT064445)
      • ANNEXA-R
      • ANNEXA-4
      • Milling et al (2023)
      • Phase 2 study
      • Comparative analysis of andexanet alfa and PCC
    • Other
      • Activated charcoal
      • Tranexamic acid
  • Management of bleeding
    • ROCKET AF - Nonvalvular atrial fibrillation
    • EINSTEIN - Treatment of DVT and PE
    • Registry data
  • Summary of studies assessing reversal agents for XARELTO
    • PCC
    • aPCC
    • rFVIIa
    • Andexanet alfa and other reversal agents
• Full scientific response

A video, “Effects of PCC on reversing the anticoagulant activity of XARELTO,” can be accessed below.

PCC, prothrombin complex concentrate.

XARELTO® (rivaroxaban) XARELTO - Management of bleeding and reversal agents